Karyopharm stock soars on selinexor's positive PhIIb update, plans for an NDA
After spooking some investors who were waiting all day for a promised trial update — and sending its stock down 14% on the perceived delay …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
